Dunning BE - Search Results

1

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

Dunning BE, Gerich JE. Dunning BE, et al. Endocr Rev. 2007 May;28(3):253-83. doi: 10.1210/er.2006-0026. Epub 2007 Apr 4. Endocr Rev. 2007. PMID: 17409288 Review.

2

Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats.

Balkan B, Dunning BE. Balkan B, et al. Among authors: dunning be. Diabetes. 1994 Oct;43(10):1173-9. doi: 10.2337/diab.43.10.1173. Diabetes. 1994. PMID: 7926284

3

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE. D'Alessio DA, et al. Among authors: dunning be. J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957505 Free PMC article. Clinical Trial.

4

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M. Vella A, et al. Among authors: dunning be. Diabetes. 2007 May;56(5):1475-80. doi: 10.2337/db07-0136. Epub 2007 Feb 15. Diabetes. 2007. PMID: 17303799 Free article. Clinical Trial.

5

Clinical measures of islet function: usefulness to characterize defects in diabetes.

Ahrén B, Pratley RE, Soubt M, Dunning BE, Foley JE. Ahrén B, et al. Among authors: dunning be. Curr Diabetes Rev. 2008 May;4(2):129-45. doi: 10.2174/157339908784220714. Curr Diabetes Rev. 2008. PMID: 18473760 Review.

6

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE. Mari A, et al. Among authors: dunning be. J Clin Endocrinol Metab. 2008 Jan;93(1):103-9. doi: 10.1210/jc.2007-1639. Epub 2007 Oct 9. J Clin Endocrinol Metab. 2008. PMID: 17925336 Clinical Trial.

7

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Dunning BE, Foley JE, Ahrén B. Dunning BE, et al. Diabetologia. 2005 Sep;48(9):1700-13. doi: 10.1007/s00125-005-1878-0. Epub 2005 Aug 13. Diabetologia. 2005. PMID: 16132964 Review.

8

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Matikainen N, et al. Among authors: dunning be. Diabetologia. 2006 Sep;49(9):2049-57. doi: 10.1007/s00125-006-0340-2. Epub 2006 Jul 1. Diabetologia. 2006. PMID: 16816950 Clinical Trial.

9

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. Villhauer EB, et al. Among authors: dunning be. J Med Chem. 2003 Jun 19;46(13):2774-89. doi: 10.1021/jm030091l. J Med Chem. 2003. PMID: 12801240

10

New non-sulfonylurea insulin secretagogues.

Dunning BE. Dunning BE. Expert Opin Investig Drugs. 1997 Aug;6(8):1041-8. doi: 10.1517/13543784.6.8.1041. Expert Opin Investig Drugs. 1997. PMID: 15989662

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results